In comparison to the control retina (Sham, Fig 6b), anti-vimentin immunoreactivity was also enhanced after retinal ischemia and preischemia administration of vehicle (Vehicle + I/R, Fig 6c). The gene discussed is VIM; the disease is retinal ischemia.